Plexxikon competitors

Laurent Fischer joined Tobira's Board of Directors in April 2009 and became Chief Executive Officer in 2014. Laurent Fischer brings 20 years of drug development and commercialization experience in the biopharmaceutical industry. Prior to joining Tobira full time he was Chairman and Chief Executive Officer of Jennerex Inc., a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer that was sold for up to $150 million. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics (NASDAQ: OCRX), where he licensed and developed OCR-002 the first ammonia scavenger for the treatment of complications of liver disease and oversaw the approval of Zysa®, the first treatment approved for irritable bowel syndrome in Europe. Laurent Fischer has co-founded and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. Laurent Fischer was responsible for the global launch of Sustiva® the first once-daily anti-HIV therapy, now part of the fixed dose combination therapy Atripla® and was involved in the launch of Invirase®, the first protease inhibitor, in the United States. Laurent Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Michael Morrissey is a President/CEO at EXELIXIS, INC.; Board Member at EXELIXIS, INC.; and Board Member at XW LABORATORIES INC and is based in Danville, California. He has experience at Schering AG and has worked as VP:Discovery Research at Berlex Biosciences; Senior Scientist at Novartis; and Senior VP:Discovery at EXELIXIS, INC.. Michael studied at Harvard University and University of Wisconsin Oshkosh.

Mr. Mazelsky was appointed President and Chief Executive Officer of IDEXX on October 23, 2019. Prior to his appointment, Mr. Mazelsky served as IDEXX's Interim President and Chief Executive Officer beginning on June 28, 2019. Prior to his appointment as Interim President and Chief Executive Officer, he was an Executive Vice President responsible for our North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including our IDEXX VetLab® in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business. He joined IDEXX in August 2012 as Executive Vice President. Previously, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics. Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent’s Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit from 1997 to 2000 at Agilent Technologies. From 1988 to 1996, he was in a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds a bachelor’s degree in mathematics from the University of Rochester and an M.B.A. from the University of Chicago.

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Christophe Berthoux is an Exec VP:Global Sales & Mktg/Chief Commercial Ofcr at CHARLES RIVER LABORATORIES, Member of the Board of Directors at Synexus, and Chairman at IMAGE ANALYSIS INC and is based in London, Greater London, United Kingdom. He has worked as CEO at Synexus, Chief Executive Officer at Synexus Clinical Research Ltd, and Gen Mgr:Clinical Svcs at CHARLES RIVER LABORATORIES.

Cory Wiegert is a CEO:CancerLinQ at American Society of Clinical Oncology (ASCO). He has worked as VP:Product Mgmt at INTERNATIONAL BUSINESS MACHINES CORP. Cory works or has worked at Sterling Commerce, CENTURA SOFTWARE CORP, and Safety-Kleen.